[
    [
        {
            "time": "",
            "original_text": "欧普康视：去年年报已经披露的医院都是并表的，目前医院总体上是亏损的，但每家医院都在逐年好转",
            "features": {
                "keywords": [
                    "欧普康视",
                    "医院",
                    "亏损",
                    "逐年好转"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "欧普康视：去年年报已经披露的医院都是并表的，目前医院总体上是亏损的，但每家医院都在逐年好转",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "欧普康视：阿托品滴眼液目前正在进行院内制剂中试后的检测和试验，完成后可以申请院内制剂注册，具体时长不便预测",
            "features": {
                "keywords": [
                    "欧普康视",
                    "阿托品滴眼液",
                    "检测",
                    "试验",
                    "注册"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "欧普康视：阿托品滴眼液目前正在进行院内制剂中试后的检测和试验，完成后可以申请院内制剂注册，具体时长不便预测",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业：十四五开启血制品新成长周期 重点推荐天坛生物、博雅生物等",
            "features": {
                "keywords": [
                    "医药生物",
                    "十四五",
                    "血制品",
                    "成长周期",
                    "天坛生物",
                    "博雅生物"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业：十四五开启血制品新成长周期 重点推荐天坛生物、博雅生物等",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]